Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6201 - 6208 of 12040 results
Law360's Immigration Editorial Advisory Board
March 21, 2018| News
The Uncertain State of the 340B Program: Where Are We Now?
March 21, 2018| Blog| Viewpoint
Mintz’s Health Care Enforcement Defense Group Releases Latest Qui Tam Update
March 21, 2018| Blog| Viewpoint
Straight EB-5 Extension in Proposed Omnibus Appropriations Bill
March 21, 2018| Blog| Viewpoint
The Affordable Care Act’s Contraceptive Mandate: A Loss in Massachusetts and Other Current Events
March 20, 2018| Blog| Viewpoint
TCPA Regulatory Update: FCC Releases Second Further Notice of Proposed Rulemaking
March 20, 2018| Article| Viewpoint
TCPA Class Action & Litigation Update: Are Post-Spokeo Challenges to Article III Standing in TCPA Cases Dead?
March 20, 2018| Article| Viewpoint
News & Press Releases
Mintz Welcomes Corporate Member Ruth Jin in New York
July 21, 2025
Ruth Jin has joined Mintz as a Member in the firm’s Corporate Practice with a focus on investment fund formation, liquidity strategies, governance, investment transactions, and securities offerings.
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|